Mahe Berland, Laetitia Padovani, Angélique Rome, Grégoire Pech-Gourg, Dominique Figarella-Branger and Nicolas André from the children hospital of La Timone and the Centre de Recherche en Oncologie Biologique et en Oncopharmacologie, INSERM-UMR 79 911, Aix-Marseille University, France have just published a case reported entitled : Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report in Frontiers in Pharmacology.

ABSTRACT

Atypical teratoid rhabdoid tumor (ATRT) is a rare and highly aggressive embryonal tumor of the central nervous system with a dismal prognosis and no definitive guidelines for treatment, especially at relapse or in case of refractory disease. Metronomic chemotherapy (MC) has emerged as a new treatment option in solid malignancies, with lower toxicity and is frequently combined with drug repositioning. We report a case of ATRT in an 8-year-old boy who progressed during multimodal therapy including surgical resection, chemotherapy and radiotherapy. He was treated with MC involving continuous :
 oral celecoxib
 with alternating metronomic etoposide and cyclophosphamide,
 in combination with biweekly bevacizumab
 and monthly intrathecal liposomal cytarabine.

To date, he remains clinically and symptomatically disease-free with a follow-up of 10 months. The treatment was well-tolerated. Metronomics represent a possible alternative regimen for children with recurrent or progressive ATRT.

The article is freely available on the Frontiers journal website here